103 related articles for article (PubMed ID: 23576060)
1. Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab).
Le Dantec C; Alonso R; Fali T; Montero E; Devauchelle V; Saraux A; Pers JO; Renaudineau Y
Immunol Res; 2013 Jul; 56(2-3):341-7. PubMed ID: 23576060
[TBL] [Abstract][Full Text] [Related]
2. The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses.
Chalmers SA; Ayilam Ramachandran R; Garcia SJ; Der E; Herlitz L; Ampudia J; Chu D; Jordan N; Zhang T; Parodis I; Gunnarsson I; Ding H; Shen N; Petri M; Mok CC; Saxena R; Polu KR; Connelly S; Ng CT; Mohan C; Putterman C
J Clin Invest; 2022 Jan; 132(1):. PubMed ID: 34981775
[TBL] [Abstract][Full Text] [Related]
3. Blocked ricin-conjugated T cell immunotoxins: effect of anti-CD6-blocked ricin on normal T cell function.
Rasmussen RA; Counts SL; Lambert JM; Collinson AR
Cancer Immunol Immunother; 1992; 35(5):355-63. PubMed ID: 1394340
[TBL] [Abstract][Full Text] [Related]
4. Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells.
Gurrea-Rubio M; Wu Q; Amin MA; Tsou PS; Campbell PL; Amarista CI; Ikari Y; Brodie WD; Mattichak MN; Muraoka S; Randon PM; Lind ME; Ruth JH; Mao-Draayer Y; Ding S; Shen X; Cooney LA; Lin F; Fox DA
Cancer Immunol Immunother; 2024 Jan; 73(2):34. PubMed ID: 38280067
[TBL] [Abstract][Full Text] [Related]
5. Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19.
Díaz Y; Ramos-Suzarte M; Martín Y; Calderón NA; Santiago W; Viñet O; La O Y; Oyarzábal JPA; Pérez Y; Lorenzo G; Cepeda M; Saavedra D; Mazorra Z; Estevez D; Lorenzo-Luaces P; Valenzuela C; Caballero A; Leon K; Crombet T; Hidalgo CJ
Gerontology; 2020; 66(6):553-561. PubMed ID: 33105142
[TBL] [Abstract][Full Text] [Related]
6. Long-term therapy with itolizumab is safe and effective for patients with moderate to severe psoriasis: Results from an expanded-access program.
Falcón Lincheta L; Saumell Nápoles Y; Gray Lovio OR; Viqueira Fuentesfría AM; Pérez Alonso T; Batista Romagoza M; Urquiza Rodríguez A; Mantecón Fernández B; Bautista Jerez HA; Fernández de Armas D; Martínez Matute ES; León García Y; Oramas Fernández DK; Marrero Chavez Y; Fernandez Lorente A; Valls Hung AR; Lorenzo-Luaces P; Valenzuela Silva C; Moreno E; Hernández-Casaña P
Int Immunopharmacol; 2024 May; 134():112225. PubMed ID: 38759368
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
Krupashankar DS; Dogra S; Kura M; Saraswat A; Budamakuntla L; Sumathy TK; Shah R; Gopal MG; Narayana Rao T; Srinivas CR; Bhat R; Shetty N; Manmohan G; Sai Krishna K; Padmaja D; Pratap DV; Garg V; Gupta S; Pandey N; Khopkar U; Montero E; Ramakrishnan MS; Nair P; Ganapathi PC
J Am Acad Dermatol; 2014 Sep; 71(3):484-92. PubMed ID: 24703722
[TBL] [Abstract][Full Text] [Related]
8. ALCAM and CD6--multiple sclerosis risk factors.
Wagner M; Bilinska M; Pokryszko-Dragan A; Sobczynski M; Cyrul M; Kusnierczyk P; Jasek M
J Neuroimmunol; 2014 Nov; 276(1-2):98-103. PubMed ID: 25216742
[TBL] [Abstract][Full Text] [Related]
9. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.
Rodriguez PC; Torres-Moya R; Reyes G; Molinero C; Prada D; Lopez AM; Hernandez IM; Hernandez MV; Martinez JP; Hernandez X; Casaco A; Ramos M; Avila Y; Barrese Y; Montero E; Hernandez P
Results Immunol; 2012; 2():204-11. PubMed ID: 24371585
[TBL] [Abstract][Full Text] [Related]
10. CD6-mediated inhibition of T cell activation via modulation of Ras.
Henriques SN; Oliveira L; Santos RF; Carmo AM
Cell Commun Signal; 2022 Nov; 20(1):184. PubMed ID: 36414966
[TBL] [Abstract][Full Text] [Related]
11. Exploration of the pathogenesis of Sjögren's syndrome via DNA methylation and transcriptome analyses.
Du Y; Li J; Wu J; Zeng F; He C
Clin Rheumatol; 2022 Sep; 41(9):2765-2777. PubMed ID: 35562622
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation.
Rambaldi B; Kim HT; Arihara Y; Asano T; Reynolds C; Manter M; Halpern M; Weber A; Koreth J; Cutler C; Gooptu M; Nikiforow S; Ho VT; Antin JH; Romee R; Ampudia J; Ng C; Connelly S; Soiffer RJ; Ritz J
Haematologica; 2022 Nov; 107(11):2617-2629. PubMed ID: 35484649
[TBL] [Abstract][Full Text] [Related]
13. Gene Variation at Immunomodulatory and Cell Adhesion Molecules Loci Impacts Primary Sjögren's Syndrome.
Casadó-Llombart S; Gheitasi H; Ariño S; Consuegra-Fernández M; Armiger-Borràs N; Kostov B; Ramos-Casals M; Brito-Zerón P; Lozano F
Front Med (Lausanne); 2022; 9():822290. PubMed ID: 35372412
[TBL] [Abstract][Full Text] [Related]
14. Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance.
Consuegra-Fernández M; Martínez-Florensa M; Aranda F; de Salort J; Armiger-Borràs N; Lozano T; Casares N; Lasarte JJ; Engel P; Lozano F
Front Immunol; 2017; 8():594. PubMed ID: 28611770
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up.
Simonin L; Pasquier E; Leroyer C; Cornec D; Lemerle J; Bendaoud B; Hillion S; Pers JO; Couturaud F; Renaudineau Y
Clin Rev Allergy Immunol; 2017 Aug; 53(1):14-27. PubMed ID: 27342459
[TBL] [Abstract][Full Text] [Related]
16. Immunological evaluation of rheumatoid arthritis patients treated with itolizumab.
Aira LE; Hernández P; Prada D; Chico A; Gómez JA; González Z; Fuentes K; Viada C; Mazorra Z
MAbs; 2016; 8(1):187-95. PubMed ID: 26466969
[TBL] [Abstract][Full Text] [Related]
17. Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis.
Menon R; David BG
Clin Cosmet Investig Dermatol; 2015; 8():215-22. PubMed ID: 25945063
[TBL] [Abstract][Full Text] [Related]
18. Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab.
Aira LE; López-Requena A; Fuentes D; Sánchez L; Pérez T; Urquiza A; Bautista H; Falcón L; Hernández P; Mazorra Z
MAbs; 2014; 6(3):783-93. PubMed ID: 24594862
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
